BACKGROUND AND PURPOSE: The proteasome inhibitor model of Parkinson's disease (PD) appears to reproduce many of the important behavioural, imaging, pathological and biochemical features of the human disease. However, the mechanisms involved in the lactacystin-induced, mitochondria-mediated apoptotic pathway remain poorly defined. EXPERIMENTAL APPROACH: We have used lactacystin as a specific inhibitor of the 20S proteasome in the dopaminergic neuroblastoma cell line SH-SY5Y. We over-expressed a green fluorescent protein (GFP)-Bax fusion protein in these cells to study localization of Bax. Free radical scavengers were used to assess the role of reactive oxygen species (ROS) in these pathways. KEY RESULTS: Lactacystin triggered a concentration-dependent increase in cell death mediated by the mitochondrial apoptotic pathway, and induced a change in mitochondrial membrane permeability accompanied by cytochrome c release. The participation of Bax protein was more critical than the formation of the permeability transition pore in mitochondria. GFP-Bax over-expression demonstrated Bax redistribution from the cytosol to mitochondria after the addition of lactacystin. ROS, but not p38 mitogen-activated protein kinase, participated in lactacystin-induced mitochondrial Bax translocation. Lactacystin disrupted the intracellular redox state by increasing ROS production and depleting endogenous antioxidant systems such as glutathione (GSH). Pharmacological depletion of GSH, using L-buthionine sulphoxide, potentiated lactacystin-induced cell death. Lactacystin sensitized neuroblastoma cells to oxidative damage, induced by subtoxic concentrations of 6-hydroxydopamine. CONCLUSIONS AND IMPLICATIONS: The lactacystin-induced, mitochondrial-mediated apoptotic pathway involved interactions between ROS, GSH and Bax. Lactacystin could constitute a potential factor in the development of sporadic PD.
BACKGROUND AND PURPOSE: The proteasome inhibitor model of Parkinson's disease (PD) appears to reproduce many of the important behavioural, imaging, pathological and biochemical features of the human disease. However, the mechanisms involved in the lactacystin-induced, mitochondria-mediated apoptotic pathway remain poorly defined. EXPERIMENTAL APPROACH: We have used lactacystin as a specific inhibitor of the 20S proteasome in the dopaminergic neuroblastoma cell line SH-SY5Y. We over-expressed a green fluorescent protein (GFP)-Bax fusion protein in these cells to study localization of Bax. Free radical scavengers were used to assess the role of reactive oxygen species (ROS) in these pathways. KEY RESULTS:Lactacystin triggered a concentration-dependent increase in cell death mediated by the mitochondrial apoptotic pathway, and induced a change in mitochondrial membrane permeability accompanied by cytochrome c release. The participation of Bax protein was more critical than the formation of the permeability transition pore in mitochondria. GFP-Bax over-expression demonstrated Bax redistribution from the cytosol to mitochondria after the addition of lactacystin. ROS, but not p38 mitogen-activated protein kinase, participated in lactacystin-induced mitochondrial Bax translocation. Lactacystin disrupted the intracellular redox state by increasing ROS production and depleting endogenous antioxidant systems such as glutathione (GSH). Pharmacological depletion of GSH, using L-buthionine sulphoxide, potentiated lactacystin-induced cell death. Lactacystin sensitized neuroblastoma cells to oxidative damage, induced by subtoxic concentrations of 6-hydroxydopamine. CONCLUSIONS AND IMPLICATIONS: The lactacystin-induced, mitochondrial-mediated apoptotic pathway involved interactions between ROS, GSH and Bax. Lactacystin could constitute a potential factor in the development of sporadic PD.
Authors: P Piccioli; C Porcile; S Stanzione; M Bisaglia; A Bajetto; R Bonavia; T Florio; G Schettini Journal: J Neurosci Res Date: 2001-12-15 Impact factor: 4.164
Authors: Joaquín Jordán; María F Galindo; Daniel Tornero; Carmen González-García; Valentín Ceña Journal: J Neurochem Date: 2004-04 Impact factor: 5.372
Authors: Yann Wan Yap; Roxana M Llanos; Sharon La Fontaine; Michael A Cater; Philip M Beart; Nam Sang Cheung Journal: Neurochem Res Date: 2015-08-29 Impact factor: 3.996
Authors: Rosa A González-Polo; José M Bravo-San Pedro; Rubén Gómez-Sánchez; Elisa Pizarro-Estrella; Mireia Niso-Santano; José M Fuentes Journal: Br J Pharmacol Date: 2013-01 Impact factor: 8.739
Authors: Sergio Perez-Alvarez; Maria E Solesio; Maria D Cuenca-Lopez; Raquel M Melero-Fernández de Mera; Carlos Villalobos; Hanna Kmita; Maria F Galindo; Joaquin Jordán Journal: Int J Cell Biol Date: 2012-06-17
Authors: Eduard Bentea; Anke Van der Perren; Joeri Van Liefferinge; Anissa El Arfani; Giulia Albertini; Thomas Demuyser; Ellen Merckx; Yvette Michotte; Ilse Smolders; Veerle Baekelandt; Ann Massie Journal: Front Behav Neurosci Date: 2015-03-31 Impact factor: 3.558